- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00635128
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine
27. April 2018 aktualisiert von: GlaxoSmithKline
Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.
Subjects aged 9 to 13 years who participated in the 711866/001 study 5 years ago will be evaluated for immune persistence and will receive a combined dTpa-IPV booster dose that will be evaluated in terms of immunogenicity, safety and reactogenicity.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
415
Phase
- Phase 4
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Berlin, Deutschland, 12627
- GSK Investigational Site
-
Berlin, Deutschland, 13507
- GSK Investigational Site
-
Berlin, Deutschland, 13355
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Ettenheim, Baden-Wuerttemberg, Deutschland, 77955
- GSK Investigational Site
-
Kehl, Baden-Wuerttemberg, Deutschland, 77694
- GSK Investigational Site
-
Oberkirch, Baden-Wuerttemberg, Deutschland, 77704
- GSK Investigational Site
-
Offenburg, Baden-Wuerttemberg, Deutschland, 77654
- GSK Investigational Site
-
-
Bayern
-
Cham, Bayern, Deutschland, 93413
- GSK Investigational Site
-
Kaufering, Bayern, Deutschland, 86916
- GSK Investigational Site
-
Landshut, Bayern, Deutschland, 84032
- GSK Investigational Site
-
Muenchen, Bayern, Deutschland, 80939
- GSK Investigational Site
-
Olching, Bayern, Deutschland, 82140
- GSK Investigational Site
-
Weilheim, Bayern, Deutschland, 82362
- GSK Investigational Site
-
-
Hessen
-
Eschwege, Hessen, Deutschland, 37269
- GSK Investigational Site
-
Koenigstein, Hessen, Deutschland, 61462
- GSK Investigational Site
-
-
Niedersachsen
-
Salzgitter, Niedersachsen, Deutschland, 38226
- GSK Investigational Site
-
Wolfenbuettel, Niedersachsen, Deutschland, 38302
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Erkrath, Nordrhein-Westfalen, Deutschland, 40699
- GSK Investigational Site
-
Goch, Nordrhein-Westfalen, Deutschland, 47574
- GSK Investigational Site
-
Guetersloh, Nordrhein-Westfalen, Deutschland, 33332
- GSK Investigational Site
-
Heiligenhaus, Nordrhein-Westfalen, Deutschland, 42579
- GSK Investigational Site
-
Kleve-Materborn, Nordrhein-Westfalen, Deutschland, 47533
- GSK Investigational Site
-
Krefeld, Nordrhein-Westfalen, Deutschland, 47798
- GSK Investigational Site
-
Loehne, Nordrhein-Westfalen, Deutschland, 32584
- GSK Investigational Site
-
Muenster, Nordrhein-Westfalen, Deutschland, 48159
- GSK Investigational Site
-
Willich, Nordrhein-Westfalen, Deutschland, 47877
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Bad Kreuznach, Rheinland-Pfalz, Deutschland, 55543
- GSK Investigational Site
-
Frankenthal, Rheinland-Pfalz, Deutschland, 67227
- GSK Investigational Site
-
Mainz, Rheinland-Pfalz, Deutschland, 55131
- GSK Investigational Site
-
Trier, Rheinland-Pfalz, Deutschland, 54294
- GSK Investigational Site
-
Worms, Rheinland-Pfalz, Deutschland, 67547
- GSK Investigational Site
-
Worms, Rheinland-Pfalz, Deutschland, 67549
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Deutschland, 01307
- GSK Investigational Site
-
Dresden, Sachsen, Deutschland, 01169
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Brunsbuettel, Schleswig-Holstein, Deutschland, 25541
- GSK Investigational Site
-
Flensburg, Schleswig-Holstein, Deutschland, 24937
- GSK Investigational Site
-
Flensburg, Schleswig-Holstein, Deutschland, 24939
- GSK Investigational Site
-
Flensburg, Schleswig-Holstein, Deutschland, 24943
- GSK Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
9 Jahre bis 13 Jahre (Kind)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
- A male or female subject who received a booster vaccination with dTpa-IPV or dTpa + IPV in study 711866/001.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Females of childbearing potential at the time of study entry must have a negative pregnancy test prior to administration of the dose of vaccine and are required to be abstinent or to use adequate contraceptive precautions for one month prior to vaccination. Subjects are required to agree to continue such precautions for two months after vaccination.
- Written informed consent obtained from both parents/ guardians of the subject; assent from the subject himself/herself should also be requested whenever possible.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months prior to the booster dose.
- Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Previous booster vaccination against tetanus, diphtheria, pertussis, or poliomyelitis since the booster dose received in study 711866/001.
- History of diphtheria, tetanus, pertussis, or poliomyelitis diseases.
- Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Administration of immunoglobulin and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
- Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
- Occurrence of any of the following adverse events (AEs) after a previous administration of a DTP vaccine: hypersensitivity reaction to any component of the vaccine, encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine, fever ≥ 40°C within 48 hours of vaccination not due to another identifiable cause, collapse or shock-like state within 48 hours of vaccination
- Persistent, severe, inconsolable screaming or crying lasting >3 hours occurring within 48 hours of receipt of a previous dose of DTP vaccine convulsions with or without fever, occurring within 3 days of vaccination.
- Acute disease at the time of enrolment.
- Pregnant or lactating female.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: BOOSTRIX-POLIO GROUP
Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
|
A single booster dose of dTpa-IPV vaccine will be administered to all subjects.
IM administration in the deltoid muscle of the non-dominant arm.
|
Experimental: BOOSTRIX + IPV MÉRIEUX GROUP
Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
|
A single booster dose of dTpa-IPV vaccine will be administered to all subjects.
IM administration in the deltoid muscle of the non-dominant arm.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Subjects With Any Grade 3 Solicited Local Symptoms
Zeitfenster: During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Assessed solicited local symptoms were pain, redness and swelling.
Grade 3 Pain: Pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
|
During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Anzahl der Probanden mit gewünschten lokalen Symptomen
Zeitfenster: Während der 4-tägigen Nachbeobachtungszeit (Tage 0–3) nach der Auffrischungsimpfung
|
Als erwünschte lokale Symptome wurden Schmerzen, Rötungen und Schwellungen beurteilt.
Beliebig = Auftreten des Symptoms unabhängig vom Intensitätsgrad.
|
Während der 4-tägigen Nachbeobachtungszeit (Tage 0–3) nach der Auffrischungsimpfung
|
Number of Subjects With Any Solicited General Symptoms
Zeitfenster: During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Assessed solicited general symptoms were fatigue, gastrointestinal, headache and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade and relationship to vaccination.
|
During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Toxoids
Zeitfenster: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Anti-D and anti-T antibody concnetration greater than or equal to (≥) 0.1 international units per milliliter (IU/mL) and ≥ 1 IU/mL have been assessed by enzyme-linked immunosorbent assay (ELISA).
Pre-vaccination sera with ELISA concentrations < 0.1 IU/mL were tested for neutralising antibodies using a Vero-cell neutralisation assay with a 0.016 IU/mL cut-off.
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Anti-D and Anti-T Antibody Concentrations
Zeitfenster: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
Zeitfenster: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA unit per milliliter (EL.U/ml).
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Zeitfenster: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Antibodies concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 Antigens
Zeitfenster: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
A seroprotected subject was defined as a subject with anti-Polio type 1, 2 and 3 antibody titers ≥ the value of 8.
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Anti-Polio 1, 2 and 3 Antibody Titers
Zeitfenster: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Antibody titers were presented as geometric mean titers (GMTs).
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Number of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN
Zeitfenster: One month after booster vaccination (At Month 1)
|
Booster vaccine response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations < 5 EL.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations < 5 EL.U/mL).
|
One month after booster vaccination (At Month 1)
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Zeitfenster: During the 31-day (Days 0-30) follow-up period after booster vaccination
|
AEs results are presented for all subjects.
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
During the 31-day (Days 0-30) follow-up period after booster vaccination
|
Number of Subjects With Serious Adverse Events (SAEs)
Zeitfenster: During the entire booster period (Month 0 to Month 1)
|
Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
During the entire booster period (Month 0 to Month 1)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Mertsola J et al. The safety of repeated administration of Boostrix™, a reduced-antigen-content dTpa booster. Abstract presented at Excellence In Paediatrics (EIP). Florence, Italy, 3-6 December 2009.
- Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother. 2012 Jul;8(7):866-72. doi: 10.4161/hv.20229. Epub 2012 Apr 9.
- Mertsola J et al. The safety of repeated administration of reduced-antigen-content dTpa boosters. Abstract presented at WSPID-6th World Congress. Buenos Aires, Argentina, 19-22 November 2009.
- Knuf M et al. The repeated administration of a reduced antigen content diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (dTpa-IPV; BoostrixTM IPV) in adolescents. Abstract presented at IDSA. Philadelphia, USA, 29 October- 1 November 2009.
- Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix IPV). Hum Vaccin. 2010 Jul;6(7):554-61. doi: 10.4161/hv.6.7.11760.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. Februar 2008
Primärer Abschluss (Tatsächlich)
8. Juli 2008
Studienabschluss (Tatsächlich)
8. Juli 2008
Studienanmeldedaten
Zuerst eingereicht
6. März 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
6. März 2008
Zuerst gepostet (Schätzen)
13. März 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
6. Juni 2018
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
27. April 2018
Zuletzt verifiziert
1. April 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Infektionen der Atemwege
- Erkrankungen der Atemwege
- Neuromuskuläre Erkrankungen
- Infektionen des zentralen Nervensystems
- Bordetella-Infektionen
- Gramnegative bakterielle Infektionen
- Bakterielle Infektionen
- Bakterielle Infektionen und Mykosen
- Grampositive bakterielle Infektionen
- Actinomycetales-Infektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Erkrankungen des Rückenmarks
- Clostridium-Infektionen
- Corynebacterium-Infektionen
- Myelitis
- Keuchhusten
- Tetanus
- Diphtherie
- Poliomyelitis
Andere Studien-ID-Nummern
- 110947
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiendaten/Dokumente
-
Datensatzspezifikation
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinischer Studienbericht
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einwilligungserklärung
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einzelner Teilnehmerdatensatz
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Studienprotokoll
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistischer Analyseplan
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Kommentiertes Fallberichtsformular
Informationskennung: 110947Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tetanus
-
Changchun BCHT Biotechnology Co.The First Affiliated Hospital of Yunnan University of Traditional Chinese... und andere MitarbeiterNoch keine Rekrutierung
-
ABO Holdings, Inc.Aktiv, nicht rekrutierendImpfung gegen Tetanus, Diphtherie und azelluläre PertussisVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenKeuchhusten | Tetanus | Diphtherie | Diphtherie-Immunisierung | Tetanus-Immunisierung | Clostridium difficile-ImmunisierungMali
-
GlaxoSmithKlineAbgeschlossenDiphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeRussische Föderation
-
GlaxoSmithKlineBeendetDiphtherie-Tetanus-azelluläre PertussisKolumbien
-
CanSino Biologics Inc.Aktiv, nicht rekrutierendDiphtherie, Tetanus und azelluläre KeuchhustenChina
-
GlaxoSmithKlineAbgeschlossenDiphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeKorea, Republik von
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenDiphtherie, Tetanus und KeuchhustenSpanien
-
GlaxoSmithKlineAbgeschlossenDiphtherie, Tetanus und Keuchhusten
-
Hospices Civils de LyonAbgeschlossen
Klinische Studien zur Boostrix-Polio
-
Norwegian Institute of Public HealthAbgeschlossenKeuchhusten | Tetanus | Diphtherie | PolioNorwegen
-
Universiteit AntwerpenChulalongkorn University; Thrasher Research Fund; Institut Pasteur de LilleAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenBelgien
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenMexiko, Chile
-
St. Justine's HospitalMinistere de la Sante et des Services SociauxAbgeschlossen
-
University of Prince Edward IslandThe Queen Elizabeth HospitalAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenDiphtherie-Tetanus-azelluläre Pertussis-ImpfstoffeRussische Föderation
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenVereinigte Staaten
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre KeuchhustenChina
-
Sanofi Pasteur, a Sanofi CompanyAbgeschlossenPoliomyelitis | PolioChina